First patients to receive experimental drug for aggressive blood cancers
NCT ID NCT06651229
Summary
This is the first study in humans to test a new drug called JNJ-90189892. It aims to find a safe and effective dose for adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not responded to prior treatments. The study will first determine the safest dose and then expand to see if the drug helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Univ. de Navarra
RECRUITINGPamplona, 31008, Spain
-
Concord Hospital
RECRUITINGConcord, 2139, Australia
-
Hosp Univ Fund Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario Virgen Rocio
RECRUITINGSeville, 41013, Spain
-
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
RECRUITINGStrasbourg, 67200, France
-
Institut Claudius Regaud
RECRUITINGToulouse, 31100, France
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13273, France
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, 3000, Australia
-
Sir Charles Gairdner Hospital
RECRUITINGNedlands, 6009, Australia
Conditions
Explore the condition pages connected to this study.